Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-? inhibitor-induced psoriasis: A case-control study - 09/11/20
Abstract |
Background |
Tumor necrosis factor-α inhibitor–induced psoriasis (TNFI psoriasis) is a paradoxical reaction characterized by development of a psoriasiform rash that mimics psoriasis vulgaris. Temporal onset variability and low incidence rates suggest that underlying risk factors or outside triggers have a role in TNFI psoriasis initiation.
Objectives |
We aimed to identify underlying risk factors and outside triggers associated with TNFI psoriasis onset.
Methods |
This case-control study included 97 patients at a tertiary care center between 2003 and 2013 who developed TNFI psoriasis. Ninety-seven control patients were matched to age, sex, disease, TNF-α inhibitor, and length of time on treatment before TNFI psoriasis onset. Patient medical records were reviewed ≥6 months immediately preceding TNFI psoriasis onset (similar equivalent time point for matched controls) for information about potential risk factors and outside factors categorized as: (1) serologic abnormalities, (2) acute events, and (3) social factors.
Results |
Compared with those of matched controls, odds ratios (ORs) were significantly higher in the TNFI psoriasis group for psoriasis family history (OR, 16.0) and acute psychological stressors (OR, 3.14) and marginally associated with tobacco use (OR, 1.76).
Conclusions |
Our results suggest that psoriasis family history, psychological stressors, and tobacco use might be risk factors for developing TNFI psoriasis. Performing detailed patient histories when considering TNFI therapy may be useful in identifying patients at risk for TNFI-psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : family history, paradoxical psoriasis, psychological stress, risk factors, smoking, TNF-α inhibitor, TNF-α inhibitor-induced psoriasis, tobacco
Abbreviations used : ANA, CI, EMR, IBD, OR, TNFI, URI
Plan
Funding sources: None. |
|
Conflicts of interest: Dr Fernandez is an investigator for Pfizer, Corbus, Mallinckrodt, Novartis, and Roche pharmaceuticals. He also receives personal research support from Mallinckrodt and Novartis; honoraria from AbbVie, UCB, Novartis, Mallinckrodt, and Celgene for consulting and advisory board participation; and honoraria from AbbVie, Novartis, and Mallinckrodt for teaching and speaking. Drs Ya, Nowacki, Khanna, Mazloom, Kabbur, and Husni and Mr Hu have no conflicts of interests to declare. |
Vol 83 - N° 6
P. 1599-1605 - décembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?